Document Type
Article
Publication Date
2016
College/Unit
School of Pharmacy
Department/Program/Center
Pharmaceutical Systems and Policy
Abstract
Objective: Medications commonly used to treat heart disease, anxiety, and depression can interact resulting in an increased risk of bleeding, warranting a cautious approach in medical decision making. This retrospective, descriptive study examined the prevalence and the factors associated with the use of both selective-serotonin reuptake inhibitor and platelet aggregation inhibitor among individuals with co-occurring atherosclerotic cardiovascular disease and anxiety or depression.
Methods: Respondents aged 22 years and older, alive throughout the study period, and diagnosed with co-occurring atherosclerotic cardiovascular disease and anxiety or depression (n=1507) in years 2007 through 2013 of the Medical Expenditures Panel Survey were included. The use of treatment was grouped as follows: selective-serotonin reuptake inhibitor and platelet aggregation inhibitor, selective-serotonin reuptake inhibitor or platelet aggregation inhibitor, and neither selective-serotonin reuptake inhibitor nor platelet aggregation inhibitor.
Results: Overall, 16.5% used both selective-serotonin reuptake inhibitor and platelet aggregation inhibitor, 61.2% used selective-serotonin reuptake inhibitor or platelet aggregation inhibitor, and 22.3% used neither selective-serotonin reuptake inhibitor nor platelet aggregation inhibitor. Respondents aged over 65years (adjusted odds ratio=1.93 (95% confidence interval=1.08–3.45)) and having a diagnosis of diabetes (adjusted odds ratio=1.63 (95% confidence interval=1.15–2.31)) and hypertension (adjusted odds ratio=1.84 (95% confidence interval=1.04–3.27)) were more likely to be prescribed the combination.
Conclusion: The drug interaction was prevalent in patients who are already at higher risk of health disparities and worse outcomes thus requiring vigilant evaluation.
Digital Commons Citation
Thornton, J. Douglas; Agarwal, Parul; and Sambamoorthi, Usha, "Use of Selective-Serotonin Reuptake Inhibitors and Platelet Aggregation Inhibitors Among Individuals with Co-Occurring Atherosclerotic Cardiovascular Disease and Depression or Anxiety" (2016). Faculty & Staff Scholarship. 2485.
https://researchrepository.wvu.edu/faculty_publications/2485
Source Citation
Thornton, J. D., Agarwal, P., & Sambamoorthi, U. (2016). Use of selective-serotonin reuptake inhibitors and platelet aggregation inhibitors among individuals with co-occurring atherosclerotic cardiovascular disease and depression or anxiety. SAGE Open Medicine, 4, 205031211668225. https://doi.org/10.1177/2050312116682255
Comments
Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).